ArticleScientific reports2024

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab.

Margherita Rimini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.